July 10, 2017
Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment
As part of this partnership, Don Francisco, who is known for his ability to connect with his audiences and inform them of the important issues of the day, will head to cities across the country to share his own personal journey of living with type 2 diabetes. These conversations will help to educate communities on some of the facts about type 2 diabetes.
"I was diagnosed with type 2 diabetes 16 years ago, and at that time I believed many things about diabetes that weren't correct. These misconceptions prevented me from making the best decisions for my health," states Don Francisco. "I joined the Basado en Hechos initiative to share what I've learned over the years with the 3.2 million Hispanics in the U.S. living with diabetes.1 Together, we can learn about the condition."
Today, Don Francisco has learned to manage his type 2 diabetes daily through medication and healthy lifestyle habits, allowing him to stay active and include the foods he loves in his meal plan.
"As a Hispanic healthcare professional who has worked within our community for many years, I've seen many patients who are hesitant to start insulin due to misconceptions about insulin treatments and diabetes management. One worry is that they will have to overhaul their lifestyle," states Dr. Frank Lavernia, Founder and Director of the North Broward Diabetes Center, Pompano Beach, FL. "Diabetes is a progressive condition that can change over time, requiring adjustments in a person's treatment plan. For many, this could include incorporating a once-daily insulin into their treatment regimen. I encourage people in our community to have an open conversation with their own healthcare providers to learn the facts about diabetes and make informed choices that may be best for their health."
Hispanics with type 2 diabetes are approximately 1.5 times less likely to adhere to insulin therapy than non-Hispanic white patients2, further evidence of the importance of being informed about type 2 diabetes and available treatment options.
"The Hispanic community is disproportionately affected by diabetes ? the prevalence of total diabetes (diagnosed/undiagnosed) among all Hispanic/Latino groups in the U.S. is 16.9%, compared to 10.2% for non-Hispanic whites adults3 ? so diabetes education in the Hispanic community is crucial," said Dr. Dara Schuster, Senior Medical Director at Lilly. "We are proud to partner with Don Francisco ? someone who is incredibly passionate about the cause and deeply connected to the Hispanic community ? to help us dispel myths and provide facts to those with diabetes, their caregivers and families so they can make informed decisions about their health and treatment plans."
Through the Basado en Hechos initiative, Don Francisco encourages people living with type 2 diabetes to start a conversation with their healthcare provider about available treatment options.
To learn more about additional misconceptions about diabetes and insulin, as well as information about a diabetes treatment, people should visit www.basadoenhechos.com.
Boehringer Ingelheim and Eli Lilly and Company
About Lilly Diabetes
About Eli Lilly and Company
About Boehringer Ingelheim
Boehringer Ingelheim is one of the world's top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. Please visit our website to learn more about how we make more health for more people through our Corporate Social Responsibility initiatives.
In 2016, Boehringer Ingelheim achieved net sales of about $17.6 billion (15.9 billion euros). R&D expenditure corresponds to 19.6 percent of its net sales.
For more information please visit www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.
PP-LD-US-1128 06/2017 ©Lilly USA, LLC 2017
SOURCE Eli Lilly and Company]]>